首页 News 正文

Bai Li Tian Heng's wholly-owned subsidiary and Bai Shi Mei Shi Gui Bao have reached a cooperation agreement on BL-B01D1

Le174
1304 0 0

Baili Tianheng disclosed on the morning of December 12th that its wholly-owned subsidiary SystImmune, Inc (hereinafter referred to as "SystImmune") and Bristol Myers Squibb (hereinafter referred to as "BMS", New York Stock Exchange code: BMY) reached a global strategic cooperation agreement on December 11 regarding the development and commercialization rights of BL-B01D1, with a potential total transaction amount of up to $8.4 billion.
The announcement shows that SystImmune and BMS are in contact with BL-B01D1 (EGFR) × The HER3 dual antibody ADC project has reached an exclusive licensing and cooperation agreement. BL-B01D1 is a potential first of its kind EGFR/HER3 bispecific antibody drug conjugate (ADC). According to the cooperation agreement, both parties will cooperate to promote the development and commercialization of BL-B01D1 in the United States. SystImmune will be solely responsible for the development, commercialization and production of BL-B01D1 in Chinese Mainland through its affiliated companies, as well as the production of some drugs for use outside Chinese Mainland. BMS will be exclusively responsible for the development and commercialization of BL-B01D1 in other regions around the world.
After the cooperation agreement takes effect, BMS will make a down payment of $800 million to SystImmune, as well as up to $500 million in recent contingent payments; After achieving development, registration, and sales milestones, SystImmune will receive an additional payment of up to $7.1 billion; The potential total transaction volume can reach up to $8.4 billion. The milestone payment stipulated in the cooperation agreement needs to meet certain conditions, and there is still uncertainty in the final milestone payment.
BL-B01D1 is an ADC based on bispecific topoisomerase inhibitors that can target both epidermal growth factor receptor and human epidermal growth factor receptor 3 (EGFR) simultaneously × HER3). We are currently conducting a global multicenter Phase I clinical study (BL-B01D1-LUNG101) to evaluate its safety and efficacy in patients with metastatic or unresectable non-small cell lung cancer (NSCLC). The early clinical research data of BL-B01D1 have been announced at the 2023 American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO) and San Antonio breast cancer Seminar (SABCS). These data show that BL-B01D1 shows promising anti-tumor activity in patients with non-small cell lung cancer and breast cancer who have progressed after standard treatment.
According to the information on Baili Tianheng's WeChat official account on the 12th, Zhu Yi, chairman and general manager of the company and chief executive of SystImmune, said, "This strategic cooperation is an important step to provide potential anti-tumor drugs to patients around the world, and we look forward to active and fruitful cooperation." Samit Hirawat, Chief Medical Officer and Head of Drug Development, said, "SystImmune's BL-B01D1 adds an ADC to our diversified research and development pipeline, which aligns well with our strategy of providing the most suitable treatment model for unmet solid tumor treatment needs. We look forward to working with SystImmune to make BL-B01D1 a differentiated treatment choice for patients in need."
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  •   知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
    caffycat
    昨天 11:18
    支持
    反对
    回复
    收藏
  •   每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
    star8699
    3 天前
    支持
    反对
    回复
    收藏
  •   上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
    goodfriendboy
    3 天前
    支持
    反对
    回复
    收藏
  •   人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
    3233340
    昨天 17:06
    支持
    反对
    回复
    收藏
Le174 新手上路
  • 粉丝

    0

  • 关注

    0

  • 主题

    3